

Book Reviews

Editorial Policy. Recently published books and journals (one copy) are invited by the Editorial Office for announcement and review in ANTICANCER RESEARCH (no fee). Each announcement should include the full title of the publication, authors or editors, the number of pages, price, year of publication, ISBN and publisher. Publishers will be notified upon receipt of books and tear sheets of reviews will be sent after publication. Books will be returned to the sender only if the announcement is rejected. Reviews will be objective and clear regarding the content, quality and usefulness of the publication.

Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publication, No. 160.

Edited by M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue, P. Boyle.
2008, pp. 897, Swiss Fr. 250.00, ISBN: 978-92-832-2160-9.
WHO Press, Geneva, Switzerland.

Cancer Incidence in Five Continents has become the recognised reference source on the incidence of cancer in populations around the world. The ninth volume has a wider coverage than before presenting data for the period 1998-2002, not only for entire populations but also for sub-populations living in the same geographic area.

This volume presents incidence data from populations all over the world for which good quality data are available. Scanning through the information gives a clear presentation of the changing cancer patterns worldwide. The nine volumes of *Cancer Incidence in Five Continents* now cover a period of approximately forty years.

Textbook of Medical Oncology. Third Edition.

Edited by F. Cavalli, H.H. Hansen, S.B. Kaye.
2004, pp. 532, £160.00, ISBN: 9-781841-843896.
Taylor & Francis, New York, NY, USA.

Effective care of the cancer patient increasingly involves systemic treatment, and as the range of available therapeutic agents continues to expand, the medical oncologist must be fully aware of the rationale for choosing specific drugs and combinations. Already acclaimed in previous editions as a key source of reference for all working in the field of Oncology, the third edition of this text has now been completely revised with important new chapters and illustrations throughout to keep it at the forefront of cancer medicine.

The third edition includes comprehensive and up-to-date discussions of a wide range of new developments in therapy. All the chapters have undergone extensive revision; some are completely new or have been rearranged in another way. Overall, this textbook is approximately 50% longer than the last edition.

Contents:

- Molecular biology of cancer;
- Principles of systemic therapy;
- Principles and examples of systemic molecular targeted therapies;

- Principles of clinical trials;
- Breast cancer;
- Gynaecological cancer;
- Head and neck cancer;
- Primary malignant tumours of the lung and pleura;
- Gastrointestinal cancer;
- Cancers of the genitor-urinary tract;
- Sarcomas;
- Leukaemias;
- Non-Hodgkin's lymphomas;
- Hodgkin lymphoma;
- Multiple myeloma;
- Management of gliomas, medulloblastoma, CNS germ cell tumours and carcinomas metastatic to the CNS;
- Malignant melanoma;
- Tumours of unknown origin;
- Symptom control and palliative care;
- Medical emergencies;
- Psycho-oncology and communication;
- Inherited predisposition to cancer: genetic counselling and clinical management;
- Agents used in the treatment of cancer.

Principles and Practice of Head and Neck Surgery and Oncology. Second Edition.

Edited by P.Q. Montgomery, P.H. Phys Evans, P.J. Gullane.
2009, pp. 658, £300.00, ISBN: 978-0415-44412-5.
Informa Healthcare, Colchester, Essex, UK.

This second edition of an award winning title has been thoroughly updated by a team of world leading head and neck surgeons, oncologists and allied healthcare professionals. *Principles and Practice of Head and Neck Surgery and Oncology, 2nd Edition*, is a comprehensive evidence-based account of the current scientific knowledge about head and neck tumors and their management. This book, with over 570 colour images, will provide a valuable source of knowledge and reference for all established specialists and trainees entrusted with the care of patients with head and neck tumors.

Contents:

- Head and Neck Malignancy: An Overview;
- Molecular Biology;
- Imaging of Head and Neck Tumors;
- Radiation Therapy for Head and Neck Cancer;
- Chemotherapy for Squamous Cell Carcinoma of the Head and Neck;
- Anaesthesia for Head and Neck Cancer;
- Nursing Care of Head and Neck Cancer Patients;
- Nutritional Support of Head and Neck Cancer Patients;
- Dental Management of the Head and Neck Patient;
- Palliation of Advanced Head and Neck Cancer;
- Tumor Site and Specific Tumors;
- Tumors of the Oral Cavity;
- Tumors of the Oropharynx;
- Tumors of the Hypopharynx;
- Tumors of the Larynx;
- Management of the Neck;

- Tumors of the Upper Jaw and Anterior Skull Base;
- Juvenile Angiofibroma;
- Tumors of the Nasopharynx;
- Tumors of the Parapharyngeal Space;
- Salivary Gland Neoplasms;
- Management of Tumors of the Temporal Bone;
- Management of Thyroid Cancer;
- Tumors of the Parathyroid Glands;
- Sarcomas of the Head and Neck;
- Non-melanoma Skin Cancer;
- Cutaneous Melanoma of the Head and Neck;
- Complications, Reconstruction, Rehabilitation and Future Developments;
- Complications in Head and Neck Cancer Surgery;
- Principles of Head and Neck Reconstruction;
- Reconstruction of the Oral cavity and Oropharynx;
- Reconstruction of the Ear;
- Principles of Nasal Reconstruction;
- Functional Voice Restoration after Total Laryngectomy;
- Future Developments in Head and Neck Cancer Therapy.

Telomeres and Telomerase in Cancer.

Edited by K. Hiyama.

2009, pp. 373, Eur 128.35, ISBN: 978-1-60327-306-0.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Telomeres and telomerase are the two pivotal players that determine the course of cellular senescence and immortalization. A universal problem for all eukaryotic cells with linear chromosomes is telomere shortening due to "end-replication problems"; its compensation by telomerase is also common from yeast to human. However, the length of telomeres, distribution of telomerase positive cells, and consequence of telomerase inhibition differ among species. *Telomeres and Telomerase in Cancer*, edited by Keiko Hiyama, focuses on human telomeres and telomerase, from basic biology and hypothesis in human normal cells and cancer cells, to clinical application as diagnostic tools and therapeutic targets in anti-cancer strategy. Cutting-edge experimental protocols for their evaluation are also included. This coverage will enable medical oncologists and students as well as basic researchers to capture the up-to-date research into the role of human telomeres and telomerase in cancer.

Stem Cells and Cancer.

Edited by R.G. Bagley, B.A. Teicher.

2009, pp. 334, Eur 92.95, ISBN: 978-1-60327-932-1.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising

approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease.

This first edition of *Stem Cells and Cancer* is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoechst dye exclusion to recognize 'side populations.' Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic *versus* epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. *Stem Cells and Cancer* represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation.

Regulatory Networks in Stem Cells.

Edited by V.K. Rajasekhar, M.C. Vemuri.

2009, pp. 601, Eur 187.20, ISBN: 978-1-60327-226-1.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Stem cells appear to be fundamental cellular units associated with the origin of multicellular organisms and have evolved to function in safeguarding the cellular homeostasis in organ tissues. The characteristics of stem cells that distinguish them from other cells have been the fascinating subjects of stem cell research. The important properties of stem cells, *such as maintenance of quiescence, self-renewal capacity, and differentiation potential*, have propelled this exciting field and presently form a common theme of research in developmental biology and medicine. The derivation of pluripotent embryonic stem cells, the prospective identification of multipotent adult stem cells, and, more recently, the induced pluripotent stem cells (popularly called iPS) are important milestones in the arena of stem cell biology. Complex networks of transcription factors, different signaling molecules, and the interaction of genetic and epigenetic events constantly modulate stem cell behavior to evoke programming and reprogramming processes in normal tissue homeostasis during development. In any given cellular scenario, the regulatory networks can pose considerable complexity and yet exert an orderly control of stem cell differentiation during normal development. An aberration in

these finely tuned processes during development usually results in a spectrum of diseases such as cancers and neurological disorders. This underscores the imminent need for a more complete understanding of molecular mechanisms underlying the regulatory circuitries required for stem cell maintenance.

This volume is an initial attempt to decipher the key factors involved in stem cell pluripotency, maintenance, and directed differentiation toward specific cell lineages and stem cell types. The presentation of the contents is such that upper-grade undergraduates, graduate students, postgraduates, and basic research as well as clinical research scientists are provided with accessible information about recent advances in the stem cell field.

The volume consists of 43 comprehensively written chapters divided into five parts: 1. Molecular regulation in stem cells. 2. Regulation by stem cells niches. 3. Epigenetic mechanisms in stem cells. 4. Signaling and regulation in select stem cell types. 5. Disease paradigms and stem cell therapeutics.

From Local Invasion to Metastatic Cancer.

Edited by S.P.L. Leong.

2009, pp. 637, Eur 144.40, ISBN: 978-1-60327-086-1.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

In human solid tumors, nodal status is the most important prognostic indicator for patients' outcome. Recent developments in the sentinel lymph node concept have resulted in a procedure to define the first draining node as the primary gateway through which the cancer will spread. In this volume a panel of international authorities takes an in-depth look at the role of the lymphovascular system in the spread of cancer. The authors summarize the findings of the Second International Symposium on Cancer Metastasis: Basis for Rational Therapy summit. Specifically, the book presents important developments in the biology and clinical understanding of cancer metastasis, describes the relationship between tumor microenvironment and proliferation, and defines the process of lymphangiogenesis and angiogenesis with special reference to cancer metastasis.

This book provides molecular oncologists, radiologists, and clinicians the necessary information to study and develop new strategies to curb the process of metastasis.

Inflammation and Cancer. Methods and Protocols. Volume 1: Experimental Models and Practical Approaches. Volume 2: Molecular Analysis and Pathways.

Edited by S. Kozlov.

2009, pp. 376 (vol. 1), pp. 401 (vol. 2), Eur 74.95 (Vol. 1),
Eur 74.95 (Vol. 2), ISBN: 978-1-934115-14-5 (vol. 1); 978-1-
60327-529-3 (vol. 2).
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

According to the most recent clinical oncology data, one out of seven newly diagnosed malignancies worldwide result from infection and chronic inflammation in conjunction with cancer.

In *Inflammation and Cancer: Methods and Protocols*, expert researchers deliver a systematic guide to techniques addressing various aspects of experimental cancer biology, selectively focused on inflammation-mediated tumorigenesis, while promoting improvisations on a per-case basis. *Volume 1, Experimental Models and Practical Approaches* provides an overview of a spectrum of techniques developed to analyze the outcomes of inflammation-mediated carcinogenesis on the tissue, cellular, and molecular levels while highlighting several diagnostic aspects, such as biomarker discovery and molecular signatures evaluation. *Volume 2: Molecular Analysis and Pathways* is devoted to an extensive description of experimental strategies aimed at investigating the molecular cross-talks between components of cell signalling chains and their ramifications in diagnostic development and drug target discovery. Written in the highly successful *Methods in Molecular Biology™* series format, chapters include brief introductions to their subjects, lists of the necessary materials and reagents, step-by-step laboratory protocols, and a notes section, which examines tips on troubleshooting and avoiding known pitfalls.

This comprehensive volume promises to serve as a vital guide and resource for investigators and clinicians working toward the goal of combating the estimated 2, 200 inflammation-related oncogenesis fatalities occurring every day.

Proteases and Cancer. Methods and Protocols.

Edited by T.M. Antalis, T.H. Bugge.

2009, pp. 221, Eur 71.64, ISBN: 978-1-60327-002-1.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

Proteases decisively contribute to cancer development and promotion by regulating the activities of growth factors/cytokines and signaling receptors, as well as the composition of the extracellular matrix, thereby suppressing cell death pathways and activating cell survival pathways. In *Proteases and Cancer: Methods and Protocols*, expert researchers bring together a wide range of current, complimentary techniques that have been developed for the specific detection and analysis of proteases and their activities in cancer biology. The volume covers vital topics including the application of proteomics technologies for the detection of protease expression in tumors, imaging proteases by activity profiling, proteomics technologies for the identification of biological substrates, detection of cell surface proteolysis, imaging of protease activity, the use of transgenic mice to determine protease function in tumor initiation and progression, and the development of anti-protease therapies for cancer. Written in the highly successful *Methods in Molecular Biology™* series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls.

Authoritative and easy to use, this volume is an ideal guide for scientists who wish to pursue the study of this important branch of cancer research and the development of unique innovative technologies to aid in that study.

Renal Cell Carcinoma. Molecular Targets and Clinical Applications. Second Edition

Edited by R.M. Bukowski, R.A. Figlin, R.J. Motzer.
2009, pp. 507, Eur 123.00, ISBN: 978-1-58829-737-2.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

In this second edition the Editors have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, *Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition* is a most valuable text on the rapidly evolving landscape of experimental therapeutics.

CNS Cancer. Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches.

Edited by E.G. Van Meir.
2009, pp. 1284, Eur 124.95, ISBN: 978-1-60327-552-1.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

Cancers of the central nervous system are among the most lethal of human neoplasms. They are recalcitrant to even intensive multimodality therapies that include surgery, radiotherapy and chemotherapy. Moreover, especially in children, the consequences of these therapies can itself be devastating and involve serious cognitive and developmental disorders. It is small wonder that such cancers have come under the intense scrutiny of each of the subspecialties of clinical care and investigation as well as attracting some of the best basic research scientists. Their joint efforts are gradually peeling away the mysteries surrounding the genesis and progression of these tumors and inroads are being steadily made into understanding why they resist therapies. This makes it an especially opportune time to assemble some of the best investigators in the field to review the "state of the art" in the various arenas that comprise the assault on CNS tumors. While the lethality of these tumors has remained dismal over the past decades, there is finally real reason for optimism as our knowledge base grows exponentially larger.

The major areas of this endeavor are displayed in this volume. Each of the chapters in the book represents illustrative examples of the road from discovery through translation to clinical importance, although many begin the journey at different parts of this continuum. This includes several chapters on incredibly clever mouse models for deciphering the genetic wiring underlying the development of CNS tumors and how that wiring might be targeted for therapeutic benefit. A great deal of attention has been

paid in the book to the development of genetic prognostic factors and biomarkers that could be used for assessing individual responses to therapies and so could lead to truly personalized medicine. Other possible prognostic factors/biomarkers that arise from an understanding of CNS tumor pathophysiology are discussed in some detail and include tumor vascularization and hypoxia. Several of the new and rapidly developing methodologies that allow these rapid advances are detailed for the reader as well and include RNA expression profiling, proteomic analyses of both tumors and biological fluids as well as profiling small non-coding RNAs and DNA modification. Finally, several chapters explore aspects of therapeutic targeting employing small molecules and combinations thereof, various sorts of cells, viruses and immune modulation.

Guide to Signal Pathways in Immune Cells.

By E. Nigel Wardle.
2009, pp. 415, Eur 106.95, ISBN: 978-1-60327-537-8.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

In this book, E. Nigel Wardle presents vital information in regards to white cells, like the neutrophils and macrophages, T and B lymphocytes, natural killer cells and mast cells, as they constitute the immune defenses against microbial invaders or tumor cells. In all such cells the necessary information processing for their activities utilizes a network of intracellular signaling pathways. As a guide this book aims to extend understanding of the basic signal transduction pathways that will be suitable for students of immunology or cell biology and for medical personnel at all levels.

Tumor Biomarker Discovery. Methods and Protocols.

Edited by M.A. Tainsky.
2009, pp. 332, Eur 80.20, ISBN: 978-1-60327-810-2.
Humana Press, c/o Springer Science + Business Media,
New York, NY, USA.

Through a variety of mechanisms, cancer cells provide the biomarker material that can lead to their own detection, which then grants clinicians the opportunity for non-invasive body fluid and tissue analysis able to indicate the presence of tumors or the level of tumor burden. In *Tumor Biomarker Discovery: Methods and Protocols*, experts in the field present detailed chapters focused on the use and development of panels of biomarker analytes while covering subjects such as nucleic acids and protein-based technologies, metabolic profiling by analytic means or spectroscopy, as well as study designs for biomarker discovery and validation. Written in the highly successful *Methods in Molecular Biology*TM series format, chapters include brief introductions to the topics, lists of the necessary materials or reagents, step-by-step laboratory protocols, and notes on troubleshooting and avoiding known pitfalls.

Cutting-edge and authoritative, *Tumor Biomarker Discovery: Methods and Protocols* is an ideal guide to the technologies that can be used to discover and validate tumor biomarker panels suitable for the presymptomatic early detection of cancer.

Biology of Stem Cells and the Molecular Basis of the Stem State.

By D. Zipori.

2009, pp. 277, Eur 139.95, ISBN: 978-1-60761-129-5.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

This volume concentrates upon adult stem cells, particularly on mesenchymal cell populations, which are the author's area of expertise. The text offers the reader a detailed description of the emergence of stem cell research and the dogmas that were created during the first decades of analysis of stem cell properties, particularly those of hemopoietic stem cells. The reader is also introduced to the commonly accepted notions regarding stem cell biology, with an emphasis on an alternative view of stemness, i.e. the stem state. In keeping with the popularity of this topic, this book addresses the major controversies and points of dispute, among researchers in the stem cell field. Overall, *Biology of Stem Cells and the Molecular Basis of the Stem State* presents a well-rounded dialogue about stem cells as it not only concentrates upon the biological elements of stem cell, but also addresses the controversy and hype currently enveloping this popular subject.

Carotenoids. Volume 5 in the series Nutrition and Health.

Edited by G. Britton, S. Liaanen-Jensen, H. Pfander.

2009, pp. 431, Eur 89.90, ISBN: 978-3-7643-7500-3.

Birkhäuser Verlag, Basel, Switzerland.

The *Carotenoids* book series provides detailed accounts of the fundamental chemistry of carotenoids and the basic methods used in carotenoid research, and critical discussions of the biochemistry, functions and applications of these important compounds.

The final volume, *Volume 5*, deals with the topic that is of greatest general interest and public concern, carotenoids in human health and nutrition. This is the era of 'functional foods', and identifying roles of chemical components of foods as important micronutrients. Carotenoids feature high on the list of these. *Volume 5* follows the carotenoid story from food to biological actions. The treatment of the fundamental properties of carotenoids, presented in the companion volume, *Volume 4*, provides a foundation. The material presented in other Volumes is also relevant to studies of biological functions and actions. Biological studies must be supported by a rigorous analytical base. The first part of *Volume 5* deals with nutrition. Methods for HPLC analysis of carotenoids in food, blood and tissues presented in *Volume 5* build on descriptions in *Volumes 1A and 1B*. Main sources of nutritionally important carotenoids in food and as supplements are summarized. Production by microbial biotechnology, and prospects for improvement of carotenoid content and composition in plants by genetic manipulation are assessed. Factors that determine the bioavailability of carotenoids – food structure, digestion, absorption, transport, deposition and localization in tissues – are discussed as well as conversion into vitamin A. This leads to a discussion of the diverse roles that

carotenoids may play in human health. The importance of dietary carotenoids as provitamin A in fighting vitamin A deficiency is emphasized. The debate about whether antioxidant activity *in vivo* may play any part in the reported biological actions of carotenoids is considered. The associations between a carotenoid-rich diet and reduced risk of the serious degenerative diseases cancer and coronary heart disease are considered and evaluated, and roles of carotenoids in maintaining eye health, protecting skin against photoaging, and stimulating the immune response system are discussed. The question of whether reported actions attributed to carotenoids may actually be mediated by vitamin A or other metabolites is addressed. Experimental strategies are discussed, including epidemiological methods and intervention trials, and studies of signalling and other mechanisms in cells in culture.

Carotenoids, Volume 5, is planned as a coordinated, integrated treatment providing up-to-date and critical research surveys by leading authorities in the field, and incorporating some background material to help make the chapters accessible to carotenoid researchers who are not specialists on the particular topic.

Copy Number Variation and Disease.

Edited by H. Kehrer-Sawatzki, D.N. Cooper.

2009, pp. 352, Eur 120.50, ISBN: 978-3-8055-9093-8.

S. Karger AG, Basel, Switzerland.

Copy number variants (CNVs) are an important source of human genomic diversity. They impact upon a diverse array of specialist fields such as evolutionary biology, predisposition to inherited disease (monogenic and complex), cancer genetics, inter-individual variation in diverse human populations, and somatic mosaicism. The important advances in CNV research that have been made over the last few years have greatly increased the awareness of the extent to which CNVs contribute to the diversity of human phenotypes, including 'single gene defects' and genomic disorders. Indeed, CNVs are now being widely investigated in genome-wide association studies to determine their influence on human disease susceptibility.

This special issue comprises a unique collection of review and original articles, which together reflect the current knowledge of CNVs while posing key questions about the structure, function and evolution of this key type of polymorphic variation in the human genome. Thus it is an invaluable source of information for evolutionary biologists as well as for human and cancer geneticists.

Early Life Origins of Human Health and Disease.

Edited by J.P. Newnham, M.G. Ross.

2009, pp. 224, Eur 99.50, ISBN: 978-3-8055-9139-3.

S. Karger AG, Basel, Switzerland.

There is compelling evidence that many of the risks leading to the most frequent chronic diseases in adulthood originate in the earliest stages of life. Adverse environmental conditions in utero and during infancy can lead to negative health effects during the subsequent lifetime of the exposed individual.

This book offers precious insights into the latest concepts and results from epidemiologic, clinical and basic studies in this burgeoning area of health care. The developmental origins of various diseases such as diabetes, obesity and cancer are examined, as well as the early programming of reproductive health and different organs. Attention is given to the impact of environmental factors such as nutrition and pollution, and the mediating genetic and epigenetic pathways are reviewed. A crucial point under discussion is the concept of environmental insults adversely affecting not only the exposed persons, but also their descendants. In addition, the economic consequences of a suboptimal start to life and the importance of preventive measures are stressed.

This publication is of great value to anyone interested in health care, notably to specialists in obstetrics, pediatrics, internal medicine, obesity, diabetes and heart disease.

Fine Needle Aspiration of Bone Tumours. The Clinical, Radiological, Cytological Approach.

By M. Åkerman, H.A. Domanski, K. Jonsson.

2009, pp. 91, Eur 94.50, ISBN: 978-3-8055-9214-7.

S. Karger AG, Basel, Switzerland.

In recent years, fine-needle aspiration cytology (FNAC) has become a widely accepted procedure in the diagnosis of bone lesions. Rapid progress in immunocytochemistry and molecular genetics has increased the role of FNAC in the investigation of primary bone lesions. The purpose of this book is to facilitate the cytological evaluation of FNA smears from skeletal lesions and to provide diagnostic criteria based on the combined evaluation of clinical data and radiographic and cytological features. The major aim is to thoroughly describe and illustrate the most common entities as well as the diagnostic use of ancillary techniques. A number of rare primary bone tumours/lesions are also illustrated.

The selection of entities illustrated in this comprehensive manual is based mainly on experience with patients referred to the Musculoskeletal Centre in Lund, Sweden, which now comprises smear data from approximately 1000 skeletal tumours/lesions collected between 1966 and 2006.

This publication will be a valuable resource for pathologists, cytopathologists, radiologists, oncologists and orthopaedic surgeons involved in the work-up and management of patients with bone lesions.

Pineal Region Tumors. Diagnosis and Treatment Options.

Edited by T. Kobayashi, L.D. Lunsford.

2009, pp. 144, Eur 105.50, ISBN: 978-3-8055-9077-8.

S. Karger AG, Basel, Switzerland.

The pineal region is an anatomic location where various intracranial tumors, in particular germ cell tumors and pineal parenchymal tumors, occur. Interestingly, pineal germ cell tumors are detected more frequently in Asian countries, including Japan, while pineal parenchymal tumors are less frequent in Asia than in the United States and Europe.

This publication takes advantage of the knowledge and experience of Japanese experts in pineal tumors, with emphasis on epidemiology and pathological diagnosis. A variety of treatment modalities including radiotherapy, radiosurgery, surgical therapy and chemotherapy are also discussed.

This valuable book will enhance the knowledge on pineal tumor treatment of not only neurosurgeons and radiation oncologists but also neurologists, neuro-oncologists, pediatricians and neuropathologists interested in pineal region tumors.

Endocrinopathy after Childhood Cancer Treatment.

Edited by W.H.B. Wallace, C.J.H. Kelnar.

2009, pp. 185, Eur 128.00, ISBN: 978-3-8055-9037-2.

S. Karger AG, Basel, Switzerland.

Continuing advances in the management of childhood malignancies result in a rapidly growing number of childhood cancer survivors. However, many of them experience treatment-induced 'late effects' including a significant number of endocrine dysfunctions.

In this book experts in the field of late effects of childhood cancer treatment offer clinical insight into pertinent issues such as the impact of cancer therapies on growth, puberty and hypothalamic and pituitary function, male and female fertility, obesity, and metabolic and bone problems.

Multidisciplinary long-term follow-up of these patients is essential to monitor, treat and prevent morbidity. Therefore this volume is of great interest to pediatric endocrinologists and oncologists, adult and reproductive endocrinologists, primary care practitioners, nurses and nurse practitioners as well as others involved in planning and delivering the holistic care which this increasingly numerous and important group of patients requires.

Signaling Mechanisms of Oxygen and Nitrogen Free Radicals.

By I.B. Afanas'ev.

2009, pp. 212, £97.00, ISBN: 978-1-4200-7374-4.

CRC Press, Taylor & Francis Group, Boca Raton, FL, USA.

Once the existence of free radicals was proven, an avalanche of studies on free radical-mediated biological processes ensued. The study of reactive oxygen and nitrogen species (ROS and RNS) is center stage in biological free radical investigations. Written by a biochemist, this volume discusses the regulatory functions of ROS and RNS in physiological and pathophysiological states.

Features:

- Presents new findings regarding the role and signaling functions of superoxide and nitric oxide in enzymatic processes.
- Explores the role of superoxide and nitric oxide in treating heart disease, cardiovascular processes, cancer, inflammation, and hereditary diseases.
- Discusses superoxide, NO, and their interactions in living systems as a framework for the discovery of novel treatments and new drugs.
- Explores how to determine the differences between damaging and regulatory signaling of free radicals.

The book provides new understanding of signaling functions in living organisms related to cardiovascular processes, cancer, inflammation, hereditary diseases, and their regulation of physiological functions such as development, aging, and senescence. This information can support the development of new drugs and novel treatment methods.

Essentials of Apoptosis. A Guide for Basic and Clinical Research.

Edited by X.-M. Yiu, Z. Dong.

2009, pp. 728, Eur 99.46, ISBN:978-1-60327-380-0.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

As a fundamental biological process, cell death and cell survival is essential to the normal homeostasis of the organism. Our knowledge on this process has been tremendously expanded in the past two decades. *Essentials of Apoptosis: A Guide for Basic and Clinical Research* was first published in 2003. It timely provided a comprehensive but concise summary of the essential information of apoptosis to both new investigators to the field and seasoned researchers seeking an integrated view of the topics. The past several years have witnessed significant new developments in the field of apoptosis and cell death in general. The concept of various types of cell death has been further developed. The studies in both basic and clinical disciplines have been greatly expanded. Notable progresses have been made in extending the work into the therapeutic arena. As a result, the field has matured considerably and developed extensive crosstalk with works in other fields. The second edition incorporates these new developments, in addition to the basic core concepts and machinery of apoptosis. Multiple new topics are added that expand the coverage on different types of cell death (apoptosis, necrosis, autophagic death and mitotic death), and on different death pathways (mediated by mitochondria, endoplasmic reticulum, death receptors, or lysosome). Furthermore, several integrated topics linking cell death to metabolism, redox status, transcription regulation are included and a systems biology approach to study apoptosis is introduced. Moreover, the roles of apoptosis and cell death in the pathogenesis of many human diseases in every major organ system are explored in details with novel therapeutic outlooks. This edition is the result of the work by more than 80 leading experts from across the world.

This volume should be valuable for both novice and seasoned investigators, as an informative reference as well as a practical guide.

Bone Metastases. A Translational and Clinical Approach.

Edited by D. Kardamakis, V. Vassiliou, E. Chou.

2009, pp. 400, Eur 139.95, ISBN:978-1-4020-9818-5.

Springer Science + Business Media, Heidelberg, Germany.

Bone Metastases: A Translational and Clinical Approach serves as both an introductory and reference book focusing on the field of metastatic bone disease. Featuring contributions from experts

in the field, this volume: describes the molecular and cellular mechanisms involved in the formation of bone metastases; comments on the role of angiogenesis; presents the newer advances made in the understanding of the clinical picture and symptoms of patients; analyses the role of bone markers in research and clinical practice; deals with all aspects of imaging modalities applied for the detection and evaluation of bone metastases.

This volume also covers the use of radiotherapy, surgery and systemic treatments for the management of metastatic bone disease and new therapeutic approaches. Moreover it may also serve as a guide for the clinical and therapeutic management of patients with metastatic bone disease.

Overall this volume presents a thorough overview of all aspects of metastatic bone disease and provides a comprehensive and concise information resource for medical researchers, oncologists, orthopaedic surgeons and clinicians.

Gene Therapy of Cancer. Methods and Protocols. Second Edition.

Edited by W. Walther, U.S. Stein.

2009, pp. 731, Eur 93.04, ISBN: 978-1-934115-85-5.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Despite various difficulties, the field of gene therapy, particularly with regard to cancer, has accumulated a tremendous amount of vital pre-clinical and clinical data. This volume fully updates the first edition with expert coverage of established and novel protocols involving both experimental and clinical approaches to cancer gene therapy. This state-of-the-art volume contains overviews of new concepts and strategies with chapters on regulatory and ethical issues, developments, problems and possible limitations of design and production of gene therapeutics as well as translational issues. Written in the highly successful *Methods in Molecular Biology™* series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls.

Cutting edge and authoritative, this volume is an ideal guide for all those who wish to explore the fast-paced and critical study of nonviral, viral, experimental and clinical cancer gene therapy.

Mitosis. Methods and Protocols.

Edited by A.D. McAinsh.

2009, pp. 345, Eur 84.95, ISBN: 978-1-60327-992-5.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

With the advent of modern methodology, the phenomenal complexity of the protein components and regulatory steps involved in mitosis has become approachable. In this volume, experts in the field provide an up-to-date collection of methods and approaches that are used to investigate the mechanism of mitosis at the molecular level. Ideal for both experienced and

novice scientists, the volume includes step-by-step methods covering inactivation of genes of interest, depletion of proteins of interest, biochemical and microscope-based techniques, and procedures to monitor and measure key mitotic processes. Written in the highly successful *Methods in Molecular Biology*TM series format, chapters include brief introductions to the respective topics, lists of the necessary materials and reagents, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls.

Comprehensive and authoritative, *Mitosis: Methods and Protocols* combines imaging, biochemical, and genetic methodologies in order to best guide researchers in their attempts to better understand the crucial processes of mitotic regulation.

Handbook of Cancer Diagnosis and Treatment Evaluation.

Edited by H.J. Schmoll, L. Van't Veer, J. Vermorken, D. Schrijvers. 2009, pp. 156, £50.00, ISBN: 978-0415-39086-6. Informa Healthcare, Colchester, Essex, UK.

The diagnosis and evaluation of treatment for cancer is a crucial topic for medical oncologists, who need to judge the various diagnostic and therapeutic factors for each cancer, the relevance of staging, and the measurement of patient response. Written by a selection of international experts, this handbook is an ideal resource for medical oncologists and those involved in screening and chemotherapy programs.

Gene Profiles in Drug Design.

Edited by B.A. Lidbury, S. Mahalingam. 2009, pp. 147, £89.00, ISBN: 978-0-8493-3733-8. CRC Press, Taylor & Francis Group, Boca Raton, FL, USA.

With the successful mapping of the human genome, we have entered an age of unprecedented opportunity in which researchers are beginning to apply this vast repository of knowledge to the treatment of human disease. Gene-profiling technologies and the concept of individualized medicine are leading to the development of drugs with enhanced specificity. This promises to lead to more effective treatment of diseases with reduced risk of side effects.

Gene Profiles in Drug Design provides insights from leaders in the pure sciences, biotechnology, and other arenas. It emphasizes the science that underpins gene profiling and drug development, and also includes clinical and ethical perspectives from experts in those fields. These explore the broadest health and social implications for this exciting field of science and discovery.

The book begins with a discussion of the future clinical impact of genetic diagnosis and gene-based drug therapies. Viroly encoded MicroRNA is reviewed, as well as the development of gene-profile-responsive antisense agents. Gene profiles are studied with respect to drug development and cancer research. RNA viruses and RNA-based drugs are also examined. Finally, ethical considerations of this groundbreaking technology are explored.

The information presented in this volume provides readers with a greater understanding of the processes and technologies

in gene-profile based drug design. Technologies are discussed in sufficient detail so that drug developers can use the book as a general desk reference. It also provides physicians, intellectual property lawyers, and investors with an important survey of emerging technologies.

Microarray Innovations. Technology and Experimentation.

Edited by G. Hardiman. 2009, pp. 314, £78.99, ISBN: 978-1-4200-9448-0. CRC Press, Taylor & Francis Group, Boca Raton, FL, USA.

In recent years, high-density DNA microarrays have revolutionized biomedical research and drug discovery efforts by the pharmaceutical industry. Their efficacy in identifying and prioritizing drug targets based on their ability to confirm a large number of gene expression measurements in parallel has become a key element in drug discovery. This volume examines the incredibly powerful nature of array technology and the ways in which it can be applied to understanding the genomic basis of disease.

This volume explores recent innovations in the microarray field and tracks the evolution of the major platforms currently used. The international panel of contributors presents a survey of the past five years' research and advancements in microarray methods and applications and their usage in drug discovery and biomedical research.

Features:

- Provides a comprehensive overview of microarray platforms;
- Reviews recent advances and innovations in array technologies;
- Examines assay automation strategies, electronic arrays and methylation arrays;
- Demonstrates new molecular diagnostic testing using microarrays.

As microarrays have evolved steadily over time from archetypical in-house complementary DNA (cDNA) arrays to robust commercial oligonucleotide platforms, there has been a migration to higher density biochips with increasing content and better analytical methodologies. This compendium summarizes the vast advances that have been made in this technology, highlighting the supreme advantages of microarray-based approaches in the field of biomedical research.

Antibody Phage Display. Methods and Protocols. Second Edition.

Edited by R. Aitken. 2009, pp. 240, Eur 79.95, ISBN: 978-1-60327-301-5. Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Since its introduction almost 20 years ago, phage display technology has revolutionized approaches to the analysis of biomedical problems, quickly impacting the fields of immunology, cell biology, biotechnology, pharmacology, and drug discovery. In *Antibody Phage Display: Methods and Protocols, Second Edition*, expert researchers explore the latest in this cutting-edge technology,

providing an invaluable resource that will guide readers in the design and execution of experiments based around antibody phage display. Chapters present a wide range of methods of isolating recombinant antibodies from phage display libraries, examine how the targets recognized by antibodies of interest can be identified, discuss the identification and exploitation of antibodies that can enter cells and bind to cytosolic targets, and include novel approaches to the expression of recombinant antibodies. Composed in the highly successful *Methods in Molecular Biology*TM series format, each chapter contains a brief introduction, step-by-step methods, a list of necessary materials, and a Notes section which shares tips on troubleshooting and avoiding known pitfalls.

Detailed and innovative, this volume is a critical handbook on phage display technology which is certain to stimulate the reader's imagination as much as it will guide future practice in the laboratory.

Cancer Stem Cells. Methods and Protocols.

Edited by J.S. Yu.

2009, pp. 283, Eur 79.95, ISBN: 978-1-58829-938-3.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Through the revolutionary concept of cancer stem cells, cancer research has been reinvigorated to study the role of these unique cells in cancer propagation and as targets of innovative therapies. In *Cancer Stem Cells: Methods and Protocols*, preeminent researchers have compiled cancer stem cell research techniques and protocols to promote healthy competition, discourse, and collaboration in this vital field. The volume covers extensive topics such as identification and isolation of cancer stem cells, animal models of cancer stem cells, methylation profiling, the contribution of the niche in the regulation of cancer stem cells, immunologic targeting, and the use of normal stem cells as a treatment, among other subjects. Written in the highly successful *Methods in Molecular Biology*TM series format, chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and expert notes on troubleshooting and avoiding known pitfalls.

Comprehensive and cutting-edge, *Cancer Stem Cells: Methods and Protocols* will aid scientists around the world in the furthering of our understanding of cancer initiation and propagation and, most importantly, in the development of novel targets for cancer therapy.

Breast Cancer in the Post-Genomic Era.

Edited by A. Giordano, N. Normanno.

2009, pp. 230, Eur 139.95, ISBN: 978-1-60327-944-4.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

Breast cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland has greatly increased over the last decade. In this volume, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of

human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. This book succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any radiation or surgical oncologist, cancer biologist or pathologist.

Predictive Diagnostics and Personalized Treatment.

Edited by O. Golubnitschaja.

2009, pp. 621, \$89.00, ISBN: 978-1-60692-737-3.

Nova Science Publishers, New York, NY, USA.

Predictive, preventive and personalized medicine offers great promise for the future practice of medicine. Essential components of this approach include well-organized population screening protocols utilizing novel diagnostic biomarkers of disease states, targeted prevention of common human pathologies, optimal treatment planning and personalized medicine thereby resulting in substantial improvement of the quality of life. This approach also offers the advantage of delivering care at potentially reduced costs to the population at large thereby addressing social and ethical issues related to access to and affordability of health care. Consequently, conventional medicine and new branches of biomedicine are currently challenging many issue-related questions: Should molecular diagnostic approaches be considered complementary or substitutive measures to conventional approaches? How reliable are biomarkers for any given pathology? How to distinguish between the highly predictive power of innovation and quackery in diagnostics? How to overcome currently well-recognizable (inter)national barriers in knowledge transfer? How to correctly educate the new generation of experts in bio- and predictive medicine? The book addresses these highly relevant issues and provides some clues for plausible solutions.

The 30 chapters of this book are divided into 7 sections: 1. Introduction; 2. Advanced technologies in preventive and personalized medicine; 3. Diabetes care: Risk factors, prediction, prevention, therapy; 4. Prediction and targeted treatment of neurodegenerative disorders; 5. Prediction of targeted treatment of cancer; 6. Predictive diagnosis in reproductive medicine and pediatrics; 7. Informatics, Economics, knowledge transfer and patients in predictive medicine.

Prostate Cancer Screening. Second Edition.

Edited by D.P. Ankerst, C.M. Tangen, I.M. Thompson.

2009, pp. 397, Eur 123.00, ISBN: 978-1-60327-980-3.

Humana Press, c/o Springer Science + Business Media, New York, NY, USA.

More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In *Prostate Cancer Screening, Second Edition*, the

world's leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world's experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, this volume is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.

Handbook of Pharmaceutical Manufacturing Formulations. Fifth Edition. Six Volumes.

By S.K. Niazi.

2009, pp. 2152 (6 volumes), £200.00 (each volume), ISBN: 978-1420081169 (vol. 1); 978-1420081183 (vol. 2); 978-1420081237 (vol. 3); 978-1420081268 (vol. 4); 978-1420081282 (vol. 5); 978-1420081305 (vol. 6). Informa Healthcare, New York, NY, USA.

This six-volume work sets the standard for authoritative, practical guidelines to the art and science of formulating drugs.

Highlights from *Compressed Solid Products, Volume One*, include:

- formulations for more than 200 of the most widely used drugs for all types of release profiles, offering, formulators a rare opportunity to start with an optimal composition;
- the essentials of what you need to be aware of when establishing a manufacturing process based on the formulations presented;
- identification and inclusion of the most popular prescription products, a critical list for the selection of products.

Highlights from *Uncompressed Solid Products, Volume Two*, include:

- the fundamental issues of good manufacturing practices;
- formulations for more than 400 pharmaceutical products, including currently approved products and innovative products such as small proteins, instantly liquifiable powders, and nanoparticles;
- access to US FDA guidelines, as well as all major guidelines around the world;
- identification and inclusion of the most often approved capsules and powders in the US.

Highlights from *Liquid Products, Volume Three*, include:

- practical details involved in complying with the current good manufacturing practice requirements in liquid manufacturing;
- access to what an FDA auditor would be looking for during a liquid manufacturing audit;
- issues that may arise during a US FDA inspection;
- the protocols used for stability testing for new drugs and new dosage forms, drawn from the most current ICH guidelines.

Highlights from *Semisolid Products, Volume Four*, include:

- coverage of over 350 formulations;
- valuable information on the difficult area of compliance;

- changes to approved new drug applications and abbreviated new drug applications;
- the evolving guidelines of ICH and when to conduct a regulatory review.

Highlights from *Over-the-Counter Products, Volume Five*, include:

- solids, liquids, and suspensions;
- practical advice on how to bring manufacturing practices into compliance with regulatory requirements;
- cGMP considerations in great detail;
- a large number of formulations of coatings of solid dosage forms.

Highlights from *Sterile Products, Volume Six*, include:

- formulations of sterile dosage forms, regulatory filing requirements of sterile preparations, and cGMP compliance, all of which are tied together in the final preparation of the CMC sections of regulatory applications;
- specifications of a manufacturing facility to manufacture compliant sterile products;
- NDA or aNDA filing requirements of sterile products;
- an alphabetical presentation of formulations of pharmaceutical products based on their generic names.

WHO World Cancer Report 2008.

Edited by P. Boyle, B. Levin.

2008, pp. 510, ISBN: 978-9283-20423-7. IARC, Lyon, France.

The rapid increase in the cancer burden represents a real crisis for public health and health systems worldwide. A major issue for many countries, even among high-resource countries, will be how to find sufficient funds to treat all cancer patients effectively and provide palliative, supportive and terminal care for the large numbers of patients, and their relatives who will be diagnosed in the coming years.

The *World Cancer Report 2008* provides a comprehensive overview of cancer for all those working in the field of health-care and research, and the general reader as well. It presents information on cancer patterns, diagnosis, causes and prevention concisely, clearly outlining the growing public health crisis. Simultaneously, there is a clear message of hope: although cancer is a great and growing devastating disease, it is largely preventable.

Current priorities for global cancer control must include a focus on low- and medium-resource countries and the identification, delivery and evaluation of effective cancer control measures. Prevention research is of overwhelming importance. Translational research in its broadest sense is of paramount importance to cancer control, covering the spectrum from translating cutting-edge scientific discovery into new approaches to cancer treatment to translating knowledge of cancer risk factors into changes in population behavior.

Women's Health Concerns Sourcebook.

Edited by S.J. Judd.

2009, pp. 711, US\$93.00, ISBN: 978-0-7808-1036-5. Omingraphics, Detroit, MI, USA.

According to the Centers for Disease Control and Prevention, 13 percent of women aged eighteen years and older are in poor, or merely fair, health. More than 12 percent of women face a limitation in their usual activities due to chronic health conditions. In addition, 62 percent of women aged twenty years and older are overweight, a key predictor of future health problems. Moreover, the medical concerns women face often differ from those of most concern to men. Autoimmune diseases strike women three times more often, while depressive disorders afflict two to three times as many women as men. Women are also disproportionately affected by disorders such as arthritis, osteoporosis, and thyroid disease.

This volume provides up-to-date information on the issues and trends in women's health and health conditions of special concern to women, including breast and gynecological concerns, sexual and reproductive concerns, ovarian cancer and other cancers affecting women, and chronic conditions such as autoimmune disease, diabetes, cardiovascular disorders, mental health concerns, and thyroid disorders. Guidelines for maintaining wellness and information about the screenings, checkups, and vaccinations recommended for women are also included, along with a glossary of related terms and a list of resources for further information.

Men's Health Concerns Sourcebook.

Edited by S.J. Judd.

2009, pp. 663, US\$93.00, ISBN: 978-0-7808-1033-4.

Omingraphics, Detroit, MI, USA.

Men face a staggering array of health concerns. According to the Centers for Disease Control and Prevention, 70 percent of American men are overweight, a key predictor of future health problems. Almost 25 percent smoke, another key risk factor. One in five American men has heart disease, and 29 percent aged twenty and older suffer from hypertension. More than 11 percent of men face a limitation in their usual activities due to chronic health conditions. In addition, the medical concerns

men face often differ from those of most concern to women. Compared with women, nearly twice as many men die of heart disease, and 50 percent more die of cancer. Men are also much more likely to commit suicide or to be victims of accidents and injuries or homicide.

This volume provides up-to-date information on the health conditions of most significance to men. It includes guidelines for maintaining wellness with facts about recommended screenings, checkups, and vaccinations. It discusses heart disease, cancer, and other leading causes of death in men, and it offers information about sexual dysfunction and disorders of the prostate, penis, and testes. Mental health concerns and sex-linked genetic disorders are also described, and the book concludes with a glossary of related terms and a directory of additional resources.

Maudsley Prescribing Guidelines. 10th Edition.

Edited by D. Taylor, C. Paton, S. Kapur.

2009, pp. 523, £50.00, ISBN: 9781841846996.

Informa Healthcare, London, UK.

The 10th edition of the *Maudsley Prescribing Guidelines* fully updates the 9th edition and includes new sections offering guidance on, for example, the use of psychotropics in atrial fibrillation, alternative routes for antidepressant administration, the treatment of velo-cardio-facial syndrome and the covert administration of medicines. Where possible guidance has been aligned with the most recently issued guidelines from UK NICE and the latest Cochrane reviews. There has also been an attempt to make the text 'future-proof' (at least for a year or two) by anticipating new drug introductions and changes in Product Licences.

The articles of the volume are divided into 8 chapters: 1. Plasma level monitoring of psychotropics and anticonvulsants; 2. Schizophrenia; 3. Bipolar disorder; 4. Depression and anxiety; 5. Children and adolescents; 6. Substance misuse; 7. Use of psychotropics in special patient groups; 8. Miscellaneous conditions and substances.

Announcements

1st International Conference on New Anticancer Therapy Strategies (ICATS 1).

2-4 June 2010, Newcastle-upon-Tyne, UK.

Information: Dr. Jacques Gilloteaux, e-mail: jagillot@yahoo.com.

Computer Assisted Radiology and Surgery (CARS 2010). 24th International Congress and Exhibition.

23-26 June 2010, Geneva, Switzerland.

Information: mailing@cars-int.org.

First International Symposium of the Journal "Hormone Molecular Biology and Clinical Investigation".

11-14 September 2010, Seefeld, Tyrol, Austria.

Information: Prof. J.R. Pasqualini, Hormones and Cancer Research Unit, 45 Boulevard Brune, 75014 Paris, France. E-mail: Jorge.Pasqualini@wanadoo.fr.

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)

Editorial Office of ANTICANCER RESEARCH,

IN VIVO, CANCER GENOMICS and PROTEOMICS.

1st km Kapandritiou-Kalamou Road

P.O. Box 22, GR-19014 Kapandriti, Attiki

GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, [®]ADLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

Correlation between WT1 Expression and Cell Proliferation in Endometrial Cancer. S. DOHI, S. OHNO, Y. OHNO, G.-I. SOMA, S. KYO, M. INOUE (<i>Ishikawa; Tokyo; Tokushima; Chiba, Japan</i>)	4887
A Study of the Postoperative Course in Cases of GIST of the Stomach. The Efficacy of Imatinib in Cases of Recurrence. D. HIGASHI, Y. WATANABE, K. HIRANO, T. SHIMOMURA, Y. EGAWA, T. TOMIYASU, Y. ISHIBASHI, K. FUTAMI, T. MAEKAWA, A. OTA, K. OSHIGE, A. IWASHITA (<i>Chikushino-shi; Kasuga-shi, Japan</i>)	4893
Role of C-Terminal Region of Yeast ADP/ATP Carrier 2 Protein: Dynamics of Flexible C-Terminal Arm. K. OHKURA, H. HORI, Y. SHINOHARA (<i>Chiba; Tokushima, Japan</i>)	4897
Reviews (pages 4717, 4795, 4845, 4855, 4861, 4867, 4879)	

* Review: Tumour Biology: Tumour-associated Inflammation <i>versus</i> Antitumor Immunity. B. MÜLLER-HÜBENTHAL, M. AZEMAR, D. LORENZEN, M. HUBER, M.A FREUDENBERG, C. GALANOS, C. UNGER, B. HILDENBRAND (<i>Freiburg; Duderstadt; Aachen, Germany</i>)	4795
MET Is Highly Expressed in Advanced Stages of Colorectal Cancer and Indicates Worse Prognosis and Mortality. A.T.T. DE OLIVEIRA, D. MATOS, A.F. LOGULLO, S.R.M. DA SILVA, R.A. NETO, A. LONGATTO-FILHO, S.S. SAAD (<i>São Paulo, Brazil; Braga, Portugal</i>)	4807
Serum Homocysteine, Cholesterol, Retinol, α -Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin. B. MELICHAR, H. KALÁBOVÁ, L. KRČMOVÁ, M. KAŠPAROVÁ, E. MALÍŘOVÁ, K. MELICHAROVÁ, M. PECKA, R. HYŠPLER, D. SOLICHOVÁ (<i>Hradec Králové; Olomouc, Czech Republic</i>)	4813
Determinants of Small Bowel Toxicity in Postoperative Pelvic Irradiation for Gynaecological Malignancies. A. HUSCHER, M. BIGNARDI, E. MAGRI, E. VITALI, N. PASINETTI, L. COSTA, P. FRATA, S.M. MAGRINI (<i>Brescia, Italy</i>)	4821
The Diagnostic and Prognostic Value of ProGRP in Lung Cancer. B. NISMAN, H. BIRAN, N. RAMU, N. HECHING, V. BARAK, T. PERETZ (<i>Jerusalem; Tel Hashomer, Israel</i>)	4827
Immunohistochemistry of DNA Mismatch Repair Enzyme MSH2 Is Not Correlated with Prognostic Data from Endometrial Carcinomas. A. SCHRÖER, F. KÖSTER, D. FISCHER, R.M. DUBITSCHER, A. WOLLHERMANN, K. DIEDRICH, M. FRIEDRICH, D. SALEHIN (<i>Lübeck; Homburg/Saar; Krefeld, Germany</i>)	4833
Circulating Tumor Cells in Solid Tumor in Metastatic and Localized Stages. L.M. MAESTRO, J. SASTRE, S.B. RAFAEL, S.B. VEGANZONES, M. VIDAURRETA, M. MARTÍN, C. OLIVIER, V.B. DE LA ORDEN, J.A. GARCIA-SAENZ, R. ALFONSO, M. ARROYO, E. DIAZ-RUBIO (<i>Madrid, Spain</i>)	4839
<i>Proceedings of the 12th Annual Meeting of the Society of Biotherapeutic Approaches, 6 December, 2008, Fukuoka, Japan; Edited by M. Torisu, M. Katano</i>	
* Review: Anti-glioma Therapy with Temozolomide and Status of the DNA-Repair Gene <i>MGMT</i> . T. FUKUSHIMA, H. TAKESHIMA, H. KATAOKA (<i>Miyazaki, Japan</i>)	4845
* Review: Mechanism for Maintaining Homeostasis in the Immune System of the Intestine. Y. TANIGUCHI, N. YOSHIOKA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan</i>)	4855
* Review: Intestinal Macrophages Involved in the Homeostasis of the Intestine Have the Potential for Responding to LPS. N. YOSHIOKA, Y. TANIGUCHI, A. YOSHIDA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan</i>)	4861
* Review: Improvement of Allergic Dermatitis via Regulation of the Th1/Th2 Immune System Balance by Macrophages Activated with Lipopolysaccharide Derived from <i>Pantoea agglomerans</i> (IP-PA1). A. YOSHIDA, C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (<i>Tokushima; Kagawa; Chiba; Yamaguchi, Japan</i>) ..	4867
Comparative Immunological Analysis of Innate Immunity Activation after Oral Administration of Wheat Fermented Extract to Teleost Fish. T. KADOWAKI, Y. YASUI, Y. TAKAHASHI, C. KOHCHI, G.-I. SOMA, H. INAGAWA (<i>Yamaguchi; Tokushima; Kagawa; Chiba, Japan</i>)	4871
* Review: Efficacy of Ligand-based Targeting for the EGF System in Cancer. F. YOTSUMOTO, A. SANUI, T. FUKAMI, K. SHIROTA, S. HORIUCHI, H. TSUJIOKA, T. YOSHIZATO, M. KUROKI, S. MIYAMOTO (<i>Fukuoka, Japan</i>)	4879

Epithelial-Myoepithelial Carcinoma of the Minor Salivary Glands: Immunohistochemical and Morphological Features. F. ANGIERO, D. SOZZI, R. SERAMONDI, M.G. VALENTE (<i>Monza; Milan, Italy</i>)	4703
Frozen Section in Axillary Sentinel Lymph Nodes for Diagnosis of Breast Cancer Micrometastasis. J.-C. TILLE, J.-F. EGGER, M. CONDREA DEVILLAZ, G. VLASTOS, M.-F. PELTE (<i>Geneva, Switzerland</i>)	4711
* Review: Immunological Similarities between Cancer and Chronic Fatigue Syndrome: The Common Link to Fatigue? M. MEEUS, W. MISTIAEN, L. LAMBRECHT, J. NIJS (<i>Antwerp; Brussels, Ghent, Belgium</i>)	4717
Utility of a Simplified Molecular Classification of Tumors for Predicting Survival of Patients with Invasive Ductal Breast Carcinoma. M.M. MUÑOZ-DÍAZ, M.J. FERNANDEZ-ACEÑERO, P. SALVADORES, J. SCHNEIDER (<i>Madrid, Spain</i>)	4727
Adenocarcinoma Corpus Uteri Stage I-II: Results of a Treatment Programme Based upon Cytometry. B. LINDAHL, A. MÅSBÄCK, J. PERSSON, J. RANSTAM, R. WILLÉN (<i>Lund; Uppsala, Sweden</i>)	4731
Optical Biopsy System Distinguishing between Hyperplastic and Adenomatous Polyps in the Colon during Colonoscopy. Z. BENES, Z. ANTOS (<i>Prague, Czech Republic</i>).....	4737
Potential Pharmacokinetic Interactions Affecting Antitumor Drug Disposition in Cancer Patients. J. LEMACHATTI, D. LEVÉQUE, L. BERETZ, J.P. BERGERAT (<i>Strasbourg, France</i>).....	4741
Superiority of Magnetic Resonance Imaging Over Conventional Radiographs in Multiple Myeloma. M. ENGELHARDT, M. KLEBER, A. FRYDRYCHOWICZ, G. PACHE, A. SCHMITT-GRÄFF, R. WÄSCH, B.G.M. DURIE (<i>Freiburg, Germany; Los Angeles, CA, USA</i>)	4745
Expression of CXCR4 and its Ligand SDF-1 in Intestinal-type Gastric Cancer Is Associated with Lymph Node and Liver Metastasis. S. IWASA, T. YANAGAWA, J. FAN, R. KATOH (<i>Kanagawa; Yamanashi; Tsukuba, Japan</i>).....	4751
Gastric Metastases Originating from Breast Cancer: Report of 8 Cases and Review of the Literature. D. PECTASIDES, A. PSYRRI, K. PLIARCHOPOULOU, T. FLOROS, G. PAPAXOINIS, M. SKONDRA, G. PAPATSIBAS, A. MACHERAS, G. ATHANASAS, P. ARAPANTONI-DATIOTI, T. ECONOMOPOULOS (<i>Athens; Piraeus, Greece</i>).....	4759
Psychosocial Risk Scale (PRS) for Breast Cancer in Patients with Breast Disease: A Prospective Case-Control Study in Kuopio, Finland. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>).....	4765
Radioimmunotherapy of Heavily Pre-treated, Non-Hodgkin's Lymphoma Patients: Efficacy and Safety in a Routine Setting. F. CICONE, R. BALDINI, M.C. COX, E. RUSSO, F. TORELLI, A. TOFANI, F. SCOPINARO (<i>Rome, Italy</i>).....	4771
Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy. S. OHNO, S. KYO, S. MYOJO, S. DOHI, J. ISHIZAKI, K.-I. MIYAMOTO, S. MORITA, J.-I. SAKAMOTO, T. ENOMOTO, T. KIMURA, Y. OKA, A. TSUBOI, H. SUGIYAMA, M. INOUE (<i>Tokyo; Ishikawa; Kanagawa; Aichi; Osaka, Japan</i>).....	4779
Relevance of Oropharyngeal Cancer Lymph Node Metastases in the Submandibular Triangle and the Posterior Triangle Apex. S. WIEGAND, J. ESTERS, H.-H. MÜLLER, T. JÄCKER, G. PAPASPYROU, M. ROEßLER, J.A. WERNER, A.M. SESTERHENN (<i>Marburg, Germany</i>)	4785
Retrospective Analysis of Concurrent vs. Sequential Administration of Radiotherapy and Hormone Therapy Using Aromatase Inhibitor for Hormone Receptor-positive Postmenopausal Breast Cancer. M. ISHITOBI, Y. KOMOIKE, K. MOTOMURA, H. KOYAMA, K. NISHIYAMA, H. INAJI (<i>Osaka, Japan</i>).....	4791

Postoperative Radiotherapy for Localized Prostate Cancer: Clinical Significance of Nadir Prostate-specific Antigen Value within 12 Months. K. OGAWA, K. NAKAMURA, T. SASAKI, H. ONISHI, M. KOIZUMI, M. ARAYA, N. MUKUMOTO, MI. MITSUMORI, T. TESHIMA (<i>Okinawa; Oita; Fukuoka; Yamanashi; Osaka; Kyoto, Japan</i>).....	4605
Ibadronate May Prevent Colorectal Carcinogenesis in Mice with Ulcerative Colitis. S. SASSA, H. OKABE, N. NEMOTO, H. KIKUCHI, H. KUDO, S. SAKAMOTO (<i>Tokyo; Chiba, Japan</i>).....	4615
Mitogenic Activity of Zeranol in Human Breast Cancer Cells Is Enhanced by Leptin and Suppressed by Gossypol. P. XU, W. YE, R. JEN, S.-H. LIN, C.-T. KUO, Y.C. LIN (<i>Columbus; Cincinnati OH, USA; Jinhua, Zhejiang, PRC</i>).....	4621
Cyclopamine and Quercetin Suppress the Growth of Leukemia and Lymphoma Cells. T. KAWAHARA, N. KAWAGUCHI-IHARA, Y. OKUHASHI, M. ITOH, N. NARA, S. TOHDA (<i>Tokyo, Japan</i>).....	4629
Ovarian Renin–Angiotensin System-regulating Aminopeptidases Are Involved in Progesterone Overproduction in Rats with Mammary Tumours Induced by N-Methyl Nitrosourea. M. DEL PILAR CARRERA, M.J. RAMÍREZ-EXPÓSITO, M.J. GARCÍA, M.D. MAYAS, J.M. MARTÍNEZ-MARTOS (<i>Jaén; Santafé; Málaga, Spain</i>).....	4633
The Akt and ERK Activation by Platinum-based Chemotherapy in Ovarian Cancer is Associated with Favorable Patient Outcome. T. OHTA, M. ISOBE, T. TAKAHASHI, M. SAITOH-SEKIGUCHI, T. MOTOYAMA, H. KURACHI (<i>Yamagata, Japan</i>).....	4639
BCL6-translocations Affect the Phenotype of Follicular Lymphomas Only in the Absence of t(14;18)IgH/BCL2. W. GOLLUB, B. STASSEK, T. HUCKHAGEL, H.-W. BERND, M. KROKOWSKI, H. MERZ, A.C. FELLER, C. THORNS (<i>Luebeck, Germany</i>).....	4649
The Arylhydrocarbon Receptor Is Only Marginally Involved in the Antileukemic Effects of its Ligand Curcumin. A. GOERGENS, M. FRERICKS, C. ESSER (<i>Düsseldorf, Germany</i>).....	4657

Clinical Studies

Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy. M. TULLOCH-REID, M.C. SKARULIS, S.I. SHERMAN, N.J. SARLIS, L. SANTARPIA (<i>Bethesda, MD; Houston, TX, USA; Florence, Italy</i>).....	4665
Differential Expression of CD3 ζ Message and Protein in Tumor Infiltrating Lymphocytes from Solid Tumor Specimens and Malignant Ascites from Patients with Ovarian Carcinoma. J. PAPPAS, A.D. WOLFSON, W.J. JUNG, E.L. OLESZAK, C.W. HELM, R.S. FREEDMAN, A.Y. TSYGANKOV, C.D. PLATSOUKAS (<i>Philadelphia, PA; Houston, TX, USA</i>).....	4673
Altered Glucose Metabolism During Chemoradiation for Head and Neck Cancer. N.P. NGUYEN, P. VOS, V. VINH-HUNG, T.L. BOROK, S. DUTTA, U. KARLSSON, H. LEE, T. MARTINEZ, B.-H. JO, L.M. NGUYEN, N. NGUYEN, S. SALLAH (<i>Tucson, AZ; Greenville, NC; Dallas, TX; Los Angeles, CA; Marshfield, WI; Shreveport, LA; Ann Arbor, MI, USA; Geneva, Switzerland; Athens, Greece</i>).....	4683
Preoperative Chemotherapy with S-1 and Cisplatin for Highly Advanced Gastric Cancer. A. NASHIMOTO, H. YABUSAKI, S. NAKAGAWA, Y. TAKII, Y. TSUCHIYA, T. OTSUO (<i>Niigata, Japan</i>).....	4689
Patients with Clinical/Radiological Hyperplasia of Mammary Glands Show Pathological Persistence of Temperature of Skin Points. H. LI, X. SHEN, J. YING, L. ZHAO, M. JIN, S. THU, C. SUN, F. VOORHORST, H. SOILAND, T. LENDE, J.P. BAAK (<i>Shanghai, PRC; Stavanger; Bergen, Norway; Amsterdam, The Netherlands</i>).....	4697

The Anti-angiogenic Activity of NSITC, a Specific Cathepsin L Inhibitor. A. REBBAA, F. CHU, T. SUDHA, C. GALLATI, U. DIER, E. DYSKIN, M. YALCIN, C. BIANCHINI, O. SHAKER, S.A. MOUSA (<i>Rensselaer, NY; Chicago, IL, USA; Cairo, Egypt</i>)	4473
Numerical Abnormalities of Chromosome 9 and <i>p16^{CDKN2A}</i> Gene Deletion Detected by FISH in Non-small Cell Lung Cancer. A.D. PANANI, K. MALIAGA, A. BABANARAKI, I. BELLENIS (<i>Athens, Greece</i>)	4483
Development and Characterization of HAT-sensitive Ewing Tumour Cells for Immunotherapy. C. PFEIFLE, K. REINHARDT, S. HEINS, S. BURDACH, M.S. STAEGE (<i>Halle; München, Germany</i>)	4489
IL-6 Regulates MMP-10 Expression via JAK2/STAT3 Signaling Pathway in a Human Lung Adenocarcinoma Cell Line. X. ZHANG, P. YIN, D. DI, G. LUO, L. ZHENG, J. WEI, J. ZHANG, Y. SHI, J. ZHANG, N. XU (<i>Changzhou, PRC; Lund, Sweden</i>)	4497
Aloe-emodin Induces Cell Death through S-Phase Arrest and Caspase-dependent Pathways in Human Tongue Squamous Cancer SCC-4 Cells. T.-H. CHIU, W.-W. LAI, T.-C. HSIA, J.-S. YANG, T.-Y. LAI, P.-P. WU, C.-Y. MA, C.-C. YEH, C.-C. HO, H.-F. LU, W.G. WOOD, J.-G. CHUNG (<i>Taichung; Taipei, Taiwan, ROC; Minneapolis, MN, USA</i>)	4503
Establishment of Imageable Model of T-cell Lymphoma Growing in Syngenic Mice. D. VETVICKA, O. HOVORKA, L. KOVAR, B. RIHOVA (<i>Prague, Czech Republic</i>)	4513
Antiproliferative and Pro-apoptotic Effects of <i>Uncaria tomentosa</i> in Human Medullary Thyroid Carcinoma Cells. B. RINNER, Z.X. LI, H. HAAS, V. SIEGL, S. STURM, H. STUPPNER, R. PFRAGNER (<i>Graz; Innsbruck, Austria; Shanghai, PRC</i>)	4519
Role of the Pharmaceutical Excipients in the Tamoxifen Activity on MCF-7 and Vero Cell Cultures. T. ROSSI, V. IANNUCELLI, G. COPPI, E. BRUNI, G. BAGGIO (<i>Modena, Italy</i>)	4529
Significance of Methylation Status and the Expression of <i>RECK</i> mRNA in Lung Tissue of Patients with NSCLC. M. PESTA, V. KULDA, O. TOPOLCAN, J. SAFRANEK, J. VRZALOVA, R. CERNY, L. HOLUBEC (<i>Pilsen, Czech Republic</i>)	4535
Catalase Protects Tumor Cells from Apoptosis Induction by Intercellular ROS Signaling. W. BECHTEL, G. BAUER (<i>Freiburg, Germany</i>)	4541
Modulation of Intercellular ROS Signaling of Human Tumor Cells. W. BECHTEL, G. BAUER (<i>Freiburg, Germany</i>)	4559
Reduction of Oxidative DNA Fragmentation by Ascorbic Acid, Zinc and <i>N</i> -Acetylcysteine in Nasal Mucosa Tissue Cultures. P. BAUMEISTER, T. HUEBNER, M. REITER, S. SCHWENK-ZIEGER, U. HARRÉUS (<i>Munich, Germany</i>)	4571
Influence of Imatinib Mesylate on Radiosensitivity of Astrocytoma Cells. E. RANZA, A. BERTOLOTTI, A. FACOETTI, L. MARIOTTI, F. PASI, A. OTTOLENGHI, R. NANO (<i>Pavia, Italy</i>)	4575
<i>In Vitro</i> Effects of Dichloroacetate and CO ₂ on Hypoxic HeLa Cells. K.M. ANDERSON, J. JAJEH, P. GUINAN, M. RUBENSTEIN (<i>Chicago, IL, USA</i>)	4579
The Cytotoxic Effects of Gemtuzumab Ozogamicin (Mylotarg) in Combination with Conventional Antileukemic Agents by Isobologram Analysis <i>In Vitro</i> . M. TANAKA, Y. KANO, M. AKUTSU, S. TSUNODA, T. IZUMI, Y. YAZAWA, S. MIYAWAKI, H. MANO, Y. FURUKAWA (<i>Tochigi; Gunma, Japan</i>)	4589
Reversal of P-gp-mediated Multidrug Resistance by Bromotetrandrine <i>In Vivo</i> Is Associated with Enhanced Accumulation of Chemotherapeutical Drug in Tumor Tissue. L.-M. CHEN, Y.-J. LIANG, X. ZHANG, X.-D. SU, C.-L. DAI, F.-P. WANG, Y.-Y. YAN, L.-Y. TAO, L.-W. FU (<i>Guangzhou; Chengdu, PRC</i>)	4597

Apoptotic Signalling in HeLa Hep2 Cells Following 5 Gy of Cobalt-60 Gamma Radiation. D. ERIKSSON, P.-O. LÖFROTH, L. JOHANSSON, K. RIKLUND, T. STIGBRAND (<i>Umeå, Sweden</i>)	4361
Activation of Human Monocyte-derived Dendritic Cells <i>In Vitro</i> by Thymax, a Gross Thymic Extract. M. GHONEUM, Y. SETO, S. AGRAWAL (<i>Los Angeles; Irvine, CA, USA; Tokyo, Japan</i>)	4367
ARRY-520, a Novel KSP Inhibitor with Potent Activity in Hematological and Taxane-resistant Tumor Models. R. WOESSNER, B. TUNQUIST, C. LEMIEUX, E. CHLIPALA, S. JACKINSKY, W. DEWOLF JR., W. VOEGTLI, A. COX, S. RANA, P. LEE, D. WALKER (<i>Boulder, CO, USA</i>)	4373
Aneuploidy Is Associated with TP53 Expression but Not with BRCA1 or TERT Expression in Sporadic Colorectal Cancer. A.R. SCHJØLBERG, O.P. CLAUSEN, E. BURUM-AUENSEN, P.M. DE ANGELIS (<i>Oslo; Loerenskog, Norway</i>)	4381
An Immunocompetent Murine Model of Metastatic Mammary Cancer Accessible to Bioluminescence Imaging. M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, N.A.S. EID, Y. TANAKA, M. WATANABE, Y. OTSUKI (<i>Osaka, Japan</i>)	4389
Changes in <i>UNC5C</i> Gene Methylation during Human Gastric Carcinogenesis. K. HIBI, M. SAKATA, K. SAKURABA, Y.-H. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	4397
Voluntary Wheel Running in Rats Receiving Doxorubicin: Effects on Running Activity and Cardiac Myosin Heavy Chain. D.S. HYDOCK, K.Y. WONDERS, C.M. SCHNEIDER, R. HAYWARD (<i>Greeley, CO; Dayton, OH, USA</i>)	4401
Imexon Augments Sensitivity of Human Lymphoma Cells to Ionizing Radiation: <i>In Vitro</i> Experimental Study. H. CHO, M. KOTO, O. RIESTERER, D.P. MOLKENTINE, U. GIRI, L. MILAS, M.D. STORY, C.S. HA, U. RAJU (<i>Pusan, Korea; Sendai, Japan; Zurich, Switzerland; Houston; Dallas; San Antonio, TX, USA</i>)	4409
Differing Expression of Metalloprotease and of Adhesion Molecules in Signet-ring Cell and Intestinal Colorectal Carcinoma. D. CABIBI, A. CALASCIBETTA, F. ARAGONA, A. MARTORANA, M. CAMPIONE, R. SANGUEDOLCE (<i>Palermo, Italy</i>)	4417
p38 Inhibitor Intensified Cell Death in Antimycin A-treated As4.1 Juxtaglomerular Cells <i>via</i> the Enhancement of GSH Depletion. Y.H. HAN, H.J. MOON, B.R. YOU, S.Z. KIM, S.H. KIM, W.H. PARK (<i>JeonJu, Republic of Korea</i>)	4423
Effects of Carbon-ion Radiotherapy combined with a Novel Histone Deacetylase Inhibitor, Cyclic Hydroxamic-acid-containing Peptide 31 in Human Esophageal Squamous Cell Carcinoma. M. KANO, S. YAMADA, I. HOSHINO, K. MURAKAMI, Y. AKUTSU, H. SAKATA, T. NISHIMORI, A. USUI, Y. MIYAZAWA, T. KAMADA, H. TSUJII, H. MATSUBARA (<i>Chiba, Japan</i>)	4433
<i>PTEN</i> Loss Induces Epithelial–Mesenchymal Transition in Human Colon Cancer Cells. K.A. BOWEN, H.Q. DOAN, B.P. ZHOU, Q. WANG, Y. ZHOU, P.G. RYCHAHOU, B.M. EVERS (<i>Galveston, TX, USA</i>)	4439
Prognostic Impact of Protein Overexpression of the Proto-oncogene <i>PIM-1</i> in Gastric Cancer. U. WARNECKE-EBERZ, E. BOLLSCHWEILER, U. DREBBER, R. METZGER, S.E. BALDUS, A.H. HÖLSCHER, S. MÖNIG (<i>Cologne; Duesseldorf, Germany</i>)	4451
Sanguinarine Sensitizes Human Gastric Adenocarcinoma AGS Cells to TRAIL-mediated Apoptosis <i>via</i> Down-regulation of AKT and Activation of Caspase-3. W.Y. CHOI, C.-Y. JIN, M.H. HAN, G.-Y. KIM, N.D. KIM, W.H. LEE, S.-K. KIM, Y.H. CHOI (<i>Pusan; Busan; Jeju, South Korea</i>)	4457
Multidrug Resistance Modulation and Apoptosis Induction of Cancer Cells by Terpenic Compounds Isolated from <i>Euphorbia</i> Species. N. DUARTE, C. RAMALHETE, A. VARGA, J. MOLNÁR, M.-J.U. FERREIRA (<i>Lisbon, Portugal; Berlin, Germany; Szeged, Hungary</i>)	4467